• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血液系统恶性肿瘤患者对2019冠状病毒病信使核糖核酸疫苗的反应欠佳：在后口罩时代需要保持警惕

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.

作者信息

Agha Mounzer E, Blake Maggie, Chilleo Charles, Wells Alan, Haidar Ghady

机构信息

Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Clinical Laboratories, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

出版信息

Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. doi: 10.1093/ofid/ofab353. eCollection 2021 Jul.

DOI:10.1093/ofid/ofab353
PMID:34337100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8320282/
Abstract

We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed.

摘要

我们对67例血液系统恶性肿瘤患者在接种2剂信使核糖核酸疫苗后，检测了其针对严重急性呼吸综合征冠状病毒2的免疫球蛋白G反应。46%的患者无反应；B细胞慢性淋巴细胞白血病患者风险最高（77%无反应）。血液系统恶性肿瘤患者应继续佩戴口罩并保持社交距离。需要开展关于重新接种、加强针以及保护性体液免疫相关性的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbf/8320282/63afd45c7278/ofab353f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbf/8320282/63afd45c7278/ofab353f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbf/8320282/63afd45c7278/ofab353f0001.jpg

相似文献

1
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.血液系统恶性肿瘤患者对2019冠状病毒病信使核糖核酸疫苗的反应欠佳：在后口罩时代需要保持警惕
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. doi: 10.1093/ofid/ofab353. eCollection 2021 Jul.
2
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.mRNA-1273 新型冠状病毒疫苗在血液恶性肿瘤患者中的细胞和体液免疫原性。
Blood Adv. 2022 Feb 8;6(3):774-784. doi: 10.1182/bloodadvances.2021006101.
3
Vaccination for SARS-CoV-2 in Hematological Patients.血液系统疾病患者的 SARS-CoV-2 疫苗接种。
Acta Haematol. 2022;145(3):257-266. doi: 10.1159/000523753. Epub 2022 Feb 25.
4
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.评估血液系统疾病患者对 SARS-CoV-2 mRNA 疫苗的血清学应答。
Front Immunol. 2022 Aug 8;13:892331. doi: 10.3389/fimmu.2022.892331. eCollection 2022.
5
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
6
COVID-19 in patients with hematologic malignancy.血液恶性肿瘤患者中的 COVID-19 感染。
Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251.
7
Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?对常规抗病毒疫苗的抗体反应不理想的个体能否从 SARS-CoV-2 mRNA 疫苗接种中获得足够的抗体？
Viruses. 2022 May 3;14(5):956. doi: 10.3390/v14050956.
8
The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.mRNA COVID-19 疫苗在血液系统疾病中的体液反应：HEMVACO 研究。
Infect Dis Now. 2022 Aug;52(5):280-285. doi: 10.1016/j.idnow.2022.05.008. Epub 2022 Jun 3.
9
Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.养老院中初次接触严重急性呼吸综合征冠状病毒2的居民对BioNTech/辉瑞2019冠状病毒病疫苗的抗体反应较差。
Clin Infect Dis. 2022 Aug 24;75(1):e695-e704. doi: 10.1093/cid/ciab998.
10
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.

引用本文的文献

1
An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.一项关于索托维单抗（VIR-7831）预防严重急性呼吸综合征冠状病毒2（SARS-CoV-2）体液免疫受损的免疫功能低下个体感染2019冠状病毒病（COVID-19）的开放标签II期试验。
New Microbes New Infect. 2025 Aug 8;67:101620. doi: 10.1016/j.nmni.2025.101620. eCollection 2025 Oct.
2
COVID-19 Vaccine Experience: Loss of Humoral Response Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients and Positive Effect of Booster Dose.COVID-19疫苗接种经历：多发性骨髓瘤患者自体干细胞移植后体液免疫反应丧失及加强剂量的积极作用。
J Clin Med. 2025 Jul 1;14(13):4648. doi: 10.3390/jcm14134648.
3

本文引用的文献

1
Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening.mRNA 新冠疫苗接种后在长期护理机构老年人中的抗体反应：对重新开放的影响。
J Am Med Dir Assoc. 2021 Aug;22(8):1593-1598. doi: 10.1016/j.jamda.2021.06.006. Epub 2021 Jun 12.
2
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
3
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy.放射性配体疗法对针对严重急性呼吸综合征冠状病毒2免疫原性的影响——一项接受前列腺特异性膜抗原放射性配体疗法的转移性前列腺癌患者的回顾性单臂队列研究
Cancers (Basel). 2025 Jun 2;17(11):1865. doi: 10.3390/cancers17111865.
4
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.免疫功能低下患者接种新型冠状病毒肺炎疫苗的免疫原性（Auto-COVID-VACC）：多中心前瞻性非干预性研究方案
JMIR Res Protoc. 2025 May 26;14:e60675. doi: 10.2196/60675.
5
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.血红蛋白病患者接种新型冠状病毒疫苗后的免疫反应及突破性感染风险：单中心经验
Vaccines (Basel). 2025 Jan 23;13(2):111. doi: 10.3390/vaccines13020111.
6
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.奥密克戎时代替沙格韦单抗-西加韦单抗用于血液系统、免疫功能低下患者的SARS-CoV-2暴露前预防
Eur J Haematol. 2025 Apr;114(4):690-699. doi: 10.1111/ejh.14377. Epub 2025 Jan 6.
7
Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.新冠病毒感染住院免疫功能低下患者中与瑞德西韦相关的生存结局：奥密克戎主导时代的真实世界证据
Clin Infect Dis. 2024 Dec 13;79(Suppl 4):S149-S159. doi: 10.1093/cid/ciae510.
8
Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病的疫苗挑战：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫接种对慢性淋巴细胞白血病患者疗效的全面探索
Ann Hematol. 2024 Dec;103(12):4971-4980. doi: 10.1007/s00277-024-05869-8. Epub 2024 Jul 15.
9
Real-World Assessment of Recommended COVID-19 Vaccination Waiting Period after Chemotherapy.化疗后推荐的COVID-19疫苗接种等待期的真实世界评估。
Vaccines (Basel). 2024 Jun 18;12(6):678. doi: 10.3390/vaccines12060678.
10
Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity.保护弱势群体：满足免疫功能受损人群的 COVID-19 护理需求。
Front Immunol. 2024 May 2;15:1397040. doi: 10.3389/fimmu.2024.1397040. eCollection 2024.
巴伦替尼（Bamlanivimab）对比安慰剂对熟练护理和辅助生活设施居民和工作人员 COVID-19 发病率的影响：一项随机临床试验。
JAMA. 2021 Jul 6;326(1):46-55. doi: 10.1001/jama.2021.8828.
4
Early experience with SARs-CoV-2 mRNA vaccine breakthrough among kidney transplant recipients.肾移植受者中SARS-CoV-2 mRNA疫苗突破性感染的早期经验。
Transpl Infect Dis. 2021 Aug;23(4):e13654. doi: 10.1111/tid.13654. Epub 2021 Jul 18.
5
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.评估接受癌症治疗的患者接种 BNT162b2 信使 RNA 疫苗后针对 SARS-CoV-2 的血清阳性率。
JAMA Oncol. 2021 Aug 1;7(8):1133-1140. doi: 10.1001/jamaoncol.2021.2155.
6
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.mRNA-1273 新型冠状病毒疫苗在肾移植受者中的细胞和体液反应。
Am J Transplant. 2021 Aug;21(8):2727-2739. doi: 10.1111/ajt.16701. Epub 2021 Aug 4.
7
The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.两剂 BNT162b2 疫苗的有效性：真实世界数据分析。
Clin Infect Dis. 2022 Feb 11;74(3):472-478. doi: 10.1093/cid/ciab438.
8
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
9
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.实体器官移植受者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗系列的抗体反应。
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
10
Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019.改善 2019 冠状病毒病免疫功能低下患者的结局。
Clin Infect Dis. 2021 Sep 15;73(6):e1397-e1401. doi: 10.1093/cid/ciab397.